Autoinjectors Market

The global autoinjectors market in terms of revenue was estimated to be worth $0.9 billion in 2023 and is poised to reach $1.7 billion by 2028, growing at a CAGR of 14.0% from 2023 to 2028.The new research study consists of an industry trend analysis of the market. The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market. Where as, the autoinjector finished formulations market is projected to reach USD 136.5 billion in 2028 from USD 59.6 billion in 2023, growing a CAGR of 18.0%. Autoinjectors offer advantages during medical emergency care as they can be administered by caregivers, family and patients themselves. Also, the market has observed growing number of regulatory approvals for devices as well as autoinjector finished formulations in last three years. These factors are expected to drive the market growth. Moreover, the loss of exclusivity of biologics and growing adoption rate of treatments given in home settings are the factors expected to offer opportunities for companies operating in this market. However, injectable route of administration is commonly accompanied with needle phobia. This is expected to limit the growth of autoinjectors adoption during the forecast period.

Attractive Opportunities in the Autoinjectors Market

To know about the assumptions considered for the study, Request for Free Sample Report

Autoinjectors Market Dynamics

DRIVER: Benefits of autoinjectors in emergency medical care

Autoinjectors offer advantages including ease of administration, faster administration of medication. Conditions like anaphylactic shocks and opioid overdose require immediate medical assistance. Anaphylactic shocks are commonly caused due to food allergies, insect sting, drug allergies, among others and if not treated immediately, can be fatal. Epinephrine has always been considered as first line of treatment for anaphylaxis. The epinephrine autoinjectors offer advantages such as portability, quick administration and are beneficial for patients with the history of anaphylactic shocks. Therefore, autoinjectors play a vital role in the treatment of conditions demanding emergency medical care. These advantages offered by autoinjectors are expected to support the market growth.

RESTRAINT: Alternative modes of drug delivery such as oral, nasal among others and needle phobia

Conventionally injectable drugs have been administered using a syringe and is a painful mode of drug delivery. For this reason, the focus of healthcare professionals as well as patients is shifting to other modes of administration such as oral, nasal and topical routes. Moreover, technological advancements have also led to development of needle-free injectors as well. Moreover, the frequency of drug administration is high for diseases such as diabetes, rheumatoid arthritis, growth hormone deficiency among other conditions. Therefore, frequent injections might create needle phobia in patients of these conditions supporting the shift of these patients to other modes of drug administration.

OPPORTUNITY: Increasing shift of therapy to home settings

Home care settings are being increasingly focused on for several treatments globally. The factors that support this include advances in medical technology, large savings compared to treatments in hospital settings and evolving patient preferences among others. Moreover, the autoinjector market players are also shifting their focus on development of autoinjectors with technological advancements such as audio-visual cues for easy handling and administration, connectivity for better assistance,and large dose and volume devices for less frequent administration of drugs are collectively supporting the adoption of autoinjectors in home care setting, consequently offering opportunities in the market.

CHALLENGE: Development of autoinjectors for multiple drug viscosities

The viscosity of a drug affects various parameters of its administration.  Autoinjectors have the capability of delivering specific volume and viscosity of drugs auto specific speed of injection. The design of the autoinjector varies according to the viscosity of the drug. For instance, spring powered autoinjectors require springs with different physical features such as length thickness composition suitable to the viscosity of the drug to be administered. Therefore, one size fits all principal is not applicable to autoinjectors. Developing an auto injector suitable for different viscosities poses challenge of accommodating different injections speeds and volumes while ensuring of the safety and accuracy. Moreover, the performance of the autoinjector device can be impacted as a result of complex designing for different viscosities and volumes. However, despite these challenges, players in the market are focusing on innovation to develop autoinjectors that are compatible with a range of drug viscosities. Therefore, the impact of this challenge is expected to fade as the companies successfully develop new products to overcome this challenge.

Autoinjector Devices and Finished Formulations Market Ecosystem

Prominent companies in the market includes companies operating in the market for several years and posess diversified product portfolio, state-of-the-art technologies, and strong global sales and marketing networks. Prominent companies in the autoinjectors market include Becton, Dickinson and Company (BD) (US), Ypsomed Holding AG (Switzerland), SHL Medical (Switzerland), West Pharmaceutical Services, Inc. (US), Recipharm AB (Sweden), Haselmeier GmbH (Germany), Owen Mumford Ltd. (UK), Philip-Medisize, LLC (US), Oval Medical Technologies Ltd. (UK), Kaleo, Inc. (US), Solteam Incorporation Co., Ltd. (China), Antares Pharma, Inc. (US), and the some of the major market players for finished formulations include AbbVie Inc. (US), Amgen Inc. (US), Eli Lilly and Company (US), Novartis AG (Switzerland), Merck KGaA (Germany), Viatris Inc. (US), and Biogen (US).

The disposable segment accounted for the largest share of the usage segment in overall autoinjectors market in 2023.

Autoinjectors are categorized as reusable and disposable based on their usage. In 2023, the usage segment accounted for the largest share of the autoinjectors devices and finished formulations market. This segment’s large share can primarily be attributed to factors such as features of manual autoinjectors including patient-centric design, ease of use, especially for patients with visual impairment, low dexterity.

The subcutaneous administration segment dominated the route of administration segment in overall autoinjectors market in 2023.

Based on the route of administration, the segment is categorized into subcutaneous and intramuscular. Manual autoinjectors accounted for the largest share of the market owing to the presence of large number of drugs administered subscutaneously and addition products being approved for this route of administration.

North America was the largest market for overall autoinjectors market in 2023.

Geographically, the overall market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa. The overall market is dominated by North America in 2023 and this dominance is anticipated to continue throughout the forecast period between 2023 and 2028. The region offers favorable reimbursement on use of autoinjectors. Also, growing number of cases of anaphylactic shock is likely to support adoption of autoinjectors. Additionally, the developed countries of the region have high level of awareness about self-administration drug delivery devices which is expected to further drive the market growth in the region.

To know about the assumptions considered for the study, download the pdf brochure

The prominent players in the autoinjectors market are Becton, Dickinson and Company (BD) (US), Ypsomed Holding AG (Switzerland), SHL Medical (Switzerland), West Pharmaceutical Services, Inc. (US), Recipharm AB (Sweden), Haselmeier GmbH (Germany), Owen Mumford Ltd. (UK), Gerreshiemer AG (Germany), Philip-Medisize, LLC (US), Oval Medical Technologies Ltd. (UK), Solteam Incorporation Co., Ltd. (China), Elcam Drug Delivery Devices (E3D) (Israel), Antares Pharma, Inc. (US), Jabil, Inc. (US), and the some of the major market players for finished formulations covered in this chapter include AbbVie Inc. (US), Amgen Inc. (US), Eli Lilly and Company (US), Novartis AG (Switzerland), Merck KGaA (Germany), Viatris Inc. (US), and Biogen (US).

Autoinjectors Market Report Scope

This report categorizes the Autoinjectors Market market to forecast revenue and analyze trends in each of the following submarkets:

By Usage

• Disposable Autoinjectors
• Reusable Autoinjectors

By Technology

• Manual Autoinjectors
• Automatic Autoinjectors

By Route of Administration

• Subcutaneous
• Intramuscular

By Type

• Rheumatoid arthritis
• Diabetes
• Multiple Sclerosis
• Anaphylaxis
• Other therapy areas

By Region

• North America
  • US
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Rest of Europe (RoE)
• Asia Pacific (APAC)
  • Japan
  • India
  • China
  • South Korea
  • Rest of Asia Pacific (RoAPAC)
• Latin America
• Middle East and Africa

Recent Developments

• In May 2023, SHL Medical and MoonLake Immunotherapeutics collaborated to develop the sonelokimab autoinjector. SHL Medical’s Molly autoinjector technology will be utilized for the clinical and potential commercial supply of MoonLake’s Nanobody sonelokimab.
• In October 2022, BD partnered with Biocorp for Biocorp’s Injay technology, which adds connectivity to prefilled syringes. It is expected to aid BD in tracking adherence to self-administered injectable drugs.

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst